Dalin Li

Title: Dalin Li: Innovator in Nucleic Acid Therapeutics

Introduction

Dalin Li is a prominent inventor based in Walnut, California, known for his significant contributions to the field of nucleic acid therapeutics. With a total of nine patents to his name, he has made remarkable strides in developing methods for treating inflammatory bowel disease.

Latest Patents

Dalin Li's latest patents include innovative methods for enriching or amplifying nucleic acids in samples from patients with inflammatory bowel disease. These patents provide methods, systems, and kits for selecting patients for treatment with therapeutic agents based on the presence of genotypes associated with positive therapeutic responses. One of the therapeutic agents mentioned is an inhibitor of TL1A activity or expression, such as an anti-TL1A antibody. Another patent focuses on selecting inflammatory bowel disease subjects for treatment with an anti-TL1A antibody based on polymorphisms, further enhancing the precision of therapeutic interventions.

Career Highlights

Throughout his career, Dalin Li has worked with esteemed organizations such as Cedars-Sinai Medical Center and Prometheus Biosciences, Inc. His work in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Dalin Li has had the opportunity to work alongside notable colleagues, including Stephan R. Targan and Dermot McGovern. These collaborations have enriched his research and expanded the impact of his innovations in the medical field.

Conclusion

Dalin Li's work exemplifies the intersection of innovation and healthcare, particularly in the treatment of inflammatory bowel disease. His patents and collaborations highlight his commitment to advancing medical science and improving patient outcomes.